Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Regeneron Pharmaceuticals (REGN) shares fell 3.56% to $651.18 on Wednesday, underperforming competitors like Amgen, Moderna, and Gilead Sciences during a broadly weak market session. The stock remains 20.70% below its 52-week high of $821.11. Trading volume was notably lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. (REGN) shed 3.56% to $651.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.14% to 7,498.96 and Dow Jones Industrial Average falling 0.01% to 52,218.58.
Regeneron Pharmaceuticals Inc. closed 20.70% short of its 52-week high of $821.11, which the company reached on January 9th.
The stock underperformed when compared to some of its competitors Wednesday, as Amgen Inc. (AMGN) fell 0.05% to $366.05, Moderna Inc. (MRNA) fell 2.67% to $58.07, and Gilead Sciences Inc. (GILD) rose 0.05% to $130.34.
Trading volume (871,841) remained 168,285 below its 50-day average volume of 1.0 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 22, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-22-26 1643ET